Drug profile · INN
montelukast
APX-MONTELUKAST
montelukast (APX-MONTELUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Alphapharm Pty Ltd.
TGA: approved NMPA: clinical trials
Patents linked 1
Pipeline programs 11
News articles 0
Drug details — montelukast
- Class
- —
- Route
- —
- Patents
- 1
- Programs
- 11
- Data quality
- 0.81
Quick answer
montelukast (APX-MONTELUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Alphapharm Pty Ltd.
Key facts
INN montelukast
Brand APX-MONTELUKAST
Mechanism Cysteinyl leukotriene receptor 1 antagonist
Originator Alphapharm Pty Ltd
Mechanism of action
Cysteinyl leukotriene receptor 1 antagonist
Approval history
| Authority | Status | Date |
|---|---|---|
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related patents
Frequently asked questions
What is montelukast?
montelukast (APX-MONTELUKAST) is a cysteinyl leukotriene receptor 1 antagonist. Associated with Alphapharm Pty Ltd.
What is the brand name for montelukast?
APX-MONTELUKAST is a marketed brand name for montelukast. Check FDA Drugs@FDA for the current US label holder and prescribing information.